Screener
Kymera Therapeutics KYMR Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other current liabilities | 236 | 242 |
| Total current liabilities | $71,326 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 64,022 | 67,034 |
| Finance lease liabilities, net of current portion | 840 | 1,462 |
| Total liabilities | $136,188 | $163,148 |
| Stockholders’ equity: |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's contract liabilities?
- Kymera Therapeutics (KYMR) reported contract liabilities of $0 in Q2 2026.
- What is the long-term trend for Kymera Therapeutics's contract liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's contract liabilities has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Kymera Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude